Compare MYSZ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | VRAX |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.6K | 972.3K |
| IPO Year | 2017 | 2021 |
| Metric | MYSZ | VRAX |
|---|---|---|
| Price | $0.86 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 79.3K | ★ 152.5K |
| Earning Date | 11-13-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,000.00 | N/A |
| Revenue This Year | $38.86 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.37 | $0.10 |
| 52 Week High | $292.78 | $13.19 |
| Indicator | MYSZ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 23.94 | 27.04 |
| Support Level | $0.37 | $0.15 |
| Resistance Level | $2.60 | $2.92 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 2.61 | 7.46 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.